^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD52 inhibitor

    Related drugs:
    2d
    Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders (clinicaltrials.gov)
    P2, N=48, Recruiting, Masonic Cancer Center, University of Minnesota | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    Rituxan (rituximab) • cyclophosphamide • Campath (alemtuzumab) • melphalan • fludarabine IV • busulfan
    11d
    Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE) (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, Case Comprehensive Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Campath (alemtuzumab) • sirolimus
    19d
    Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies (clinicaltrials.gov)
    P=N/A, N=57, Active, not recruiting, Masonic Cancer Center, University of Minnesota | Recruiting --> Active, not recruiting | N=30 --> 57
    Enrollment closed • Enrollment change
    |
    cyclophosphamide • Campath (alemtuzumab) • melphalan • fludarabine IV • mesna • busulfan
    19d
    Phase 1B pilot study of itacitinib with alemtuzumab in patients with T-cell prolymphocytic leukemia. (PubMed, Blood Neoplasia)
    Continued studies evaluating JAK inhibitors in patients with T-PLL are warranted. This trial was registered at www.clinicaltrials.gov as #NCT03989466.
    Clinical • P1 data • Journal
    |
    JAK3 (Janus Kinase 3) • STAT5B (Signal Transducer And Activator Of Transcription 5B) • TCL1A (TCL1 Family AKT Coactivator A) • IL2RG (Interleukin 2 Receptor Subunit Gamma)
    |
    Campath (alemtuzumab) • itacitinib (INCB039110)
    24d
    Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, Boston Children's Hospital | Trial primary completion date: Jul 2025 --> Jul 2026
    Trial primary completion date
    |
    TERT (Telomerase Reverse Transcriptase) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • DKC1 (Dyskerin Pseudouridine Synthase 1) • ZCCHC8 (Zinc Finger CCHC-Type Containing 8) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    Campath (alemtuzumab) • fludarabine IV • cyclosporin A microemulsion
    27d
    Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders (clinicaltrials.gov)
    P1/2, N=29, Recruiting, Washington University School of Medicine | Trial completion date: Apr 2031 --> Apr 2033 | Trial primary completion date: Apr 2026 --> Apr 2028
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • Campath (alemtuzumab) • melphalan • fludarabine IV • hydroxyurea
    28d
    NCI-2022-03571: TMLI and Alemtuzumab for Treatment of Sickle Cell Disease (clinicaltrials.gov)
    P1, N=2, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting | N=20 --> 2
    Enrollment closed • Enrollment change
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    Campath (alemtuzumab) • sirolimus
    2ms
    LemKids: A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT (clinicaltrials.gov)
    P3, N=16, Terminated, Genzyme, a Sanofi Company | Active, not recruiting --> Terminated; Enrolment formally closed earlier than planned due to recruitment challenges.
    Trial termination
    |
    Lemtrada (alemtuzumab)
    2ms
    T-PLL: Observatory of Prolymphocytic Leukemia T (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, French Innovative Leukemia Organisation | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Jun 2025 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    Campath (alemtuzumab)
    3ms
    Asymptomatic T prolymphocytic leukemia: case report and literature review. (PubMed, Einstein (Sao Paulo))
    Standard therapies include alemtuzumab-based regimens and hematopoietic stem cell transplantation, although relapse rates remain high. This case underscores the need to recognize indolent presentations of T-cell prolymphocytic leukemia that may be managed conservatively. Further research is required to identify prognostic markers and optimize therapeutic strategies.
    Review • Journal
    |
    ATM (ATM serine/threonine kinase) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • STAT5B (Signal Transducer And Activator Of Transcription 5B) • TCL1A (TCL1 Family AKT Coactivator A)
    |
    ATM mutation
    |
    Campath (alemtuzumab)
    3ms
    Islet Cell Transplant for Type 1 Diabetes (clinicaltrials.gov)
    P2, N=10, Active, not recruiting, City of Hope Medical Center | Trial completion date: Oct 2025 --> Sep 2026 | Trial primary completion date: Oct 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    Campath (alemtuzumab)
    4ms
    Effect of Alemtuzumab on Microglial Activation Positron Emission Tomography (PET) in Multiple Sclerosis (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, Brigham and Women's Hospital | N=10 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    Lemtrada (alemtuzumab)